Alpha 2.0
Login Register
» Articles » PMID: 2966981

Safety and Tolerance of Trimetrexate: Results of a Phase II Multicenter Study in Patients with Metastatic Cancer Refractory to Conventional Therapy or for Which No Conventional Therapy Exists

Overview
Journal Semin Oncol
Specialty Oncology
Date 1988 Apr 1
PMID 2966981
Citations 4
Authors
J A Stewart
Affiliations
Soon will be listed here.
Citing Articles

Clinical pharmacokinetics and pharmacology of trimetrexate.

Marshall J, DeLap R Clin Pharmacokinet. 1994; 26(3):190-200.

PMID: 8194282 DOI: 10.2165/00003088-199426030-00003.

Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group.

Carlson R, Doroshow J, Odujinrin O, Flam M, Malec M, Lamborn K Invest New Drugs. 1990; 8(4):387-9.

PMID: 2150672 DOI: 10.1007/BF00198597.

Hypersensitivity reactions to trimetrexate.

Grem J, King S, Costanza M, Brown T Invest New Drugs. 1990; 8(2):211-4.

PMID: 2143501 DOI: 10.1007/BF00177263.

Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma.

Fossella F, Winn R, Holoye P, Hallinan B, Raber M, Hoelzer K Invest New Drugs. 1992; 10(4):331-5.

PMID: 1336771 DOI: 10.1007/BF00944191.